The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma

Cancer Research

Volumn 69, Issue 7, 2009, Pages 3021-3031

  Seiwert, Tanguy Y ^a   Jagadeeswaran, Ramasamy ^a   Faoro, Leonardo ^a   Janamanchi, Varalakshmi ^a   Nallasura, Vidya ^a   Dinali, Mohamed El ^a   YaIa, Soheil ^a   Kanteti, Rajani ^a   Cohen, Ezra E W ^a   Ungen, Mark W ^a   Martin, Leslie ^a   Krishnaswamy, Soundararajan ^a   Klein Szanto, Andres ^b   Christensen, James G ^c   Vokes, Everett E ^a   Salgia, Ravi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SEMAPHORIN; SMALL INTERFERING RNA; ((3Z) N (3 CHLOROPHENYL) 3 ((3,5 DIMETHYL 4 ((4 METHYLPIPERAZIN 1 YL)CARBONYL) 1H PYRROL 2 YL)METHYLENE) N METHYL 2 OXO 2,3 DIHYDRO 1H INDOLE 5 SULFONAMIDE); ((3Z)-N-(3-CHLOROPHENYL)-3-((3,5-DIMETHYL-4-((4-METHYLPIPERAZIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-N-METHYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE); ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; INDOLE DERIVATIVE; MET PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; DRUG TARGETING; GENE MUTATION; GENE NUMBER; GENE OVEREXPRESSION; GENE SEQUENCE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MUTAGENESIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENE DOSAGE; GENETIC TRANSFECTION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MOUSE; MUTATION; NUDE MOUSE; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; GENE DOSAGE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MICE; MICE, NUDE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66149135285     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2881     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Vermorken JB, Mesia R, Rivera F, et al. Plotinum-bosed chemotherapy plus cetuxlmab in head and neck cancer. N Engl J Med 2008;359:1116-1127
3. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase Ii. study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25:2171-2177
4. Grandis JR, Tweardy DJ. Elevated levels of trans- forming growth factor a and epidermal growth factor receptor messenger RNA are early markers of carcino- genesis in head and neck cancer. Cancer Res 1993:53: 3579-84
5. Guo A, Villen. J, Kornhauser J, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sei U S A 2008;105:692-697
6. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043
7. Bean J, Brennan. C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sei U S A 2007; 104:20932-20937
8. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER. (ErbB) family members. Oncogene 2008;27:3944-3956
9. Tang Z, Du R, Jiang S, et al. Dual MET-EGFR combinatorial inhibition, against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008;99: 911-922.
10. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309-325
11. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006;.12:3657-3660
12. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SUI,274 and small interfer- ing RNA in non-small cell lung cancer. Cancer Res 2005; 65:1479-1488
13. Dl Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Onco- gene 2000:19:1547-1555
14. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sei USA 2006;103:2316-2321
15. Jagadeeswaran R, Surawska H, Krishnaswamy S, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 2008:68:132-142
16. Jagadeeswaran R, Ma PC, Selwert TY, et al. Func- tional analysis of c-Met/hepatocyte growth factor pathway in. malignant pleural mesothelioma Cancer Res 2006;66:352-361
17. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272-6281
18. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-5469
19. Zou HY, Li Q, Lee JH, et al. An orally available small- molecule Inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiprolifer- ative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-4417
20. Chou TC, Talalay P. Quantitative analysis of dose- effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984:22: 27-55.
21. Coutlee F, Gravitt P, Kornegay J, et al. Use of PGMY primers in Ll consensus PCR improves detection of human papillomavirus DNA In genital samples. J Clin Microbiol 2002;40:902-907
22. Ginos MA, Page GP, Michalowicz BS, et al. Identifi- cation, of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 2004;64:55-63.
23. Purl N, Khramtsov A, Ahmed S, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 2007;67:3529-3534
24. Chen. YS, Wang JT, Chang YF, et al. Expression of hepatocyte growth factor and c-met protein is signifi- cantly associated with the progression of oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 2004;33: 209-217
25. Lo Muzio L, Leonardi R, Mignogna MD, et al. Scatter factor receptor (c-Met) as possible prognostic factor in patients with oral squamous cell carcinoma. Anticancer Res 2004;24:1063-1069
26. Morello S, Olivero M, AimetÜ M, et al. MET receptor Is overexpressed but not mutated In oral squamous cell carcinomas. J Cell Physiol 2001;189:285-290
27. Mural M, Shen X, Huang L, et al. Overexpression of c-met in. oral SCC promotes hepatocyte growth factor- induced disruption of Cadherin junctions and invasion. Int J Oncol 2004;25:831-840
28. Kim. CH, Moon SK, Bae JH, et al. Expression, of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 2006;126: 88-94.
29. Yucel OT, Sungur A, Kaya S. c-met overexpression in supraglottic laryngeal squamous cell carcinoma and its relation to lymph node metastases. Otolaryngol Head Neck Surg 2004;130:698-703.
30. Ohnishi T, Daikuhara Y. Hepatocyte growth factor/ scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. Arch Oral Biol 2003;48:797-804.
31. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational, analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008:47: 1025-1037
32. Xie Q, Liu KD, Hu MY, Zhou K. SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma. World J Gastroenterol 200.1; 7:816-820
33. Rosen EM, Laterra J, Joseph A, et al. Scatter factor expression and regulation in human glial tumors. Int J Cancer 1996:67:248-255
34. Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 antl-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68:4360-4368
35. Yonesaka K, Zejnullohu K, Homes AJ, Johnson BE, Jaime PA. Presence of amphiregulin. autocrlne-loop predicts sensitivity of EGFR wild type cancers to gefitinib and cetuximab. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16. San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract: 4958.
36. Akervall J, Guo X, Qian CN, et al. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin Cancer Res 2004; 10:8204-8213
37. Aebersold DM, Rollar A, Beer KT, Laissue J, Greiner RH, Djonov V. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bd-xL in. the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 2001;96:41-54.
38. Aebersold DM, Landt O, Berthou S, et al. Prevalence and clinical impact of Met YI253.D- activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 2003;22:8519-8523
39. Uchida D, Kawamata H, Omotehara F, et al. Role of HGF/c-met system, in. invasion, and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 2001;93:489-496
40. Cortesina G, Martone T, Galeazzi E, et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells In lymph node metastases. Int J Cancer 2000;89:286-292
41. Chung CH, Parker JS, Karaca G, et al. Molecular clas- sification of head and neck squamous cell carcinomas using patterns of gene expression Cancer Cell 2004;5:489-500.
42. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad ScI U S A 1997;94:11445-11450
43. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation, in the EGFR kinase domain. PLoS Med 2005;2:e73.
44. Jiang S, Du R, Tang Z, Kern J, Ma P. Targeted inhibition of wild type and mutated MET receptor variants in the sema, juxtamembrane and kinase domain. J Thorac Oncol 2007;2:S546, P2-139.
45. Berthou S, Aebersold DM, Schmidt LS, et al. The Met kinase inhibitor SUl 1274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 2004;23:5387-5393
46. Yonesaka K, Zejnullahu K, Homes AJ, Johnson BE, Jaime PA. Presence of amphlregulin autocrlne-loop predicts sensitivity of EGFR wild type cancers to gefitinib and cetuximab. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16;San Diego, CA Philadelphia (PA): AACR; 2008. Abstract: 4958.
47. Engelman JA. The role of phosphoinosltide 3-kinase pathway inhibitors in the treatment of lung cancer. Clin Cancer Res 2007;I3:s4637-40.
48. Cohen EE, Lingen MW, Martin LE, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005;11:8105-8108
49. Saucier C, Khoury H, Lai KM, et al. The She adaptor protein, is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc Natl Acad Sei U S A 2004:101: 2345-2350
50. Zhang YW, Su Y, Lanning N, et al. Enhanced growth of human met-expressing xenografts in a new strain, of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 2005;24:101-106